New study tracks Selumetinib's Real-World impact on kids with NF1 tumors
NCT ID NCT06175637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 80-100 Chinese children aged 3-16 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. All participants take the drug selumetinib (Koselugo) and are monitored for 24 months to see how well it works and what side effects occur in everyday medical practice. The goal is to better understand the disease and treatment patterns in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selumetinib (Koselugo)
What this could lead to
If successful, this study could confirm that selumetinib works well and is safe for Chinese children with NF1-related tumors, potentially leading to broader access and better management of the disease.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It only includes Chinese children, so findings may not apply to other populations. Side effects of selumetinib are possible, and the study does not test a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMA, PLEXIFORM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, Beijing Municipality, China
-
Research Site
Chongqing, Chongqing Municipality, China
-
Research Site
Lanzhou, Gansu, China
-
Research Site
Guangzhou, Guangdong, China
-
Research Site
Shenzhen, Guangdong, China
-
Research Site
Nanning, Guangxi, China
-
Research Site
Guiyang, Guizhou, China
-
Research Site
Shijiazhuang, Hebei, China
-
Research Site
Zhengzhou, Henan, China
-
Research Site
Wuhan, Hubei, China
-
Research Site
Changsha, Hunan, China
-
Research Site
Nanjing, Jiangsu, China
-
Research Site
Suzhou, Jiangsu, China
-
Research Site
Nanchang, Jiangxi, China
-
Research Site
Shenyang, Liaoning, China
-
Research Site
Jinan, Shandong, China
-
Research Site
Shanghai, Shanghai Municipality, China
-
Research Site
Taiyuan, Shanxi, China
-
Research Site
Xi’an, Shanxi, China
-
Research Site
Chengdu, Sichuan, China
-
Research Site
Tianjin, Tianjin Municipality, China
-
Research Site
Kunming, Yunnan, China
-
Research Site
Hangzhou, Zhejiang, China
-
Research Site
Wenzhou, Zhejiang, China
-
Research Site
Nanjing, China